Verrica Pharmaceuticals
VRCA
Market cap $57.2M

1.34 USD

+0.03

2.29%

At close Oct 7, 4:00 PM EDT

After hours

1.37

+0.03

2.24%

1 day

2.29%

5 days

-9.46%

1 month

-29.84%

3 months

-82.60%

6 months

-80.86%

Year to date

-80.32%

1 year

-66.58%

5 years

-90.55%

About: Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Employees: 100

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

621% more call options, than puts

Call options by funds: $584K | Put options by funds: $81K

120% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 10

28% more capital invested

Capital invested by funds: $106M [Q1] → $136M (+$30M) [Q2]

19% more funds holding

Funds holding: 62 [Q1] → 74 (+12) [Q2]

13% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 16

1.79% more ownership

Funds ownership: 42.16% [Q1] → 43.95% (+1.79%) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

721%

upside

Avg. target

$12

796%

upside

High target

$13

870%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

RBC Capital Gregory Renza 42% 1-year accuracy 32 / 76 met price target	721%upside $11	Outperform Maintained	4 Oct 2024
Needham Serge Belanger 53% 1-year accuracy 61 / 115 met price target	796%upside $12	Hold Downgraded	3 Oct 2024
RBC Capital Gregory Renza 42% 1-year accuracy 32 / 76 met price target	870%upside $13	Outperform Maintained	15 Aug 2024
Needham Serge Belanger 53% 1-year accuracy 61 / 115 met price target	796%upside $12	Buy Maintained	15 Aug 2024

See Analyst Rankings

Financial journalist opinion

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operating teams to reduce costs and expand access to YCANTH ® for the treatment of molluscum contagiosum.

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

NEW ORLEANS , Sept. 27, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

WEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Transcript

Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Kevin Gardner - Managing Director, LifeSci Advisors Ted White - President and Chief Executive Officer Joe Bonaccorso - Chief Commercial Officer Terry Kohler - Chief Financial Officer Gary Goldenberg - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Glen Santangelo - Jefferies Oren Livnat - H.C. Wainwright Serge Belanger - Needham Kemp Dolliver - Brookline Capital Markets Operator Good morning, and welcome to the Verrica Pharmaceuticals Second Quarter 2024 Earnings Conference Call.

Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.21 per share a year ago.

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

- Reports YCANTH ® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor –

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

VP-315 was well tolerated with no reported treatment-related serious adverse events All patients treated with VP-315 had a reduction in tumor size with an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86% Approximately 51% of lesions treated in Part 2 achieved complete histological clearance Patients with residual tumor on average achieved an approximate 71% reduction in tumor size ~3.6 million basal cell carcinomas diagnosed in the U.S. each year, which is expected to continue to grow due to aging US population, better diagnosis and increased exposure to risk factors WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced preliminary positive results from Part 2 of its Phase 2 clinical trial studying VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma.

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 14, 2024, to discuss the Company's financial results for the second quarter ended June 30, 2024, and provide an overview of topline results from Part 2 of the Phase 2 trial of VP-315 for the treatment of basal cell carcinoma.

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

7 Short-Squeeze Stocks That Could Beat Down the Bears

Short-squeeze stocks represent one of the boldest forms of contrarianism available. Simply put, it's a showdown between the bears that are attempting to profit from the downturn of a public enterprise.

7 Short-Squeeze Stocks That Could Beat Down the Bears

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

See News Rankings

Charts implemented using Lightweight Charts™